1. Home
  2. CRVS vs WEN Comparison

CRVS vs WEN Comparison

Compare CRVS & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$18.76

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

HOLD

Current Price

$7.27

Market Cap

1.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRVS
WEN
Founded
2014
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRVS
WEN
Price
$18.76
$7.27
Analyst Decision
Strong Buy
Hold
Analyst Count
5
21
Target Price
$28.00
$9.76
AVG Volume (30 Days)
7.7M
7.6M
Earning Date
03-24-2026
02-13-2026
Dividend Yield
N/A
7.11%
EPS Growth
N/A
0.63
EPS
N/A
0.95
Revenue
N/A
$2,208,190,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.79
P/E Ratio
N/A
$8.33
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$7.60
52 Week High
$26.95
$16.20

Technical Indicators

Market Signals
Indicator
CRVS
WEN
Relative Strength Index (RSI) 57.79 31.27
Support Level $18.50 $7.60
Resistance Level $21.57 $8.08
Average True Range (ATR) 1.69 0.31
MACD -0.59 -0.04
Stochastic Oscillator 10.48 0.80

Price Performance

Historical Comparison
CRVS
WEN

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About WEN Wendy's Company (The)

The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.

Share on Social Networks: